Sensibilidad a antifúngicos de levaduras patógenas emergentes

García-Martos, Pedro; Domínguez, Inmaculada; Marín, Pilar; García-Agudo, Rebeca; Aoufi, Sami; Mira, José A.

doi:10.1016/s0213-005x(01)72630-4

Cited by 29 publications

(13 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,11,29,30 It is likely that the emergence and increase of different pathogenic yeasts is due not only to a major incidence of infection among immunocompromised hosts, but also to changes in the pathogenic features of these species of yeasts and increasing resistance to antifungal agents, in particular azoles. 4 Malassezia furfur, T. asahii, Rhodotorula, Pichia anomala, C. albicans, C. lusitaniae, C. holmii, C. norvegensis, C. valida and C. dublinensis have been reported as emerging pathogenic yeasts in humans. 4 Even yeasts such as C. utilis and C. lipolytica, which are considered to be environmental pollutants and have industrial importance, have been identified as agents of fungemia, onychomycosis and systemic disease.…”

Section: Discussionmentioning

confidence: 99%

“…To a lesser extent, Candida lusitaniae, Candida holmii, Candida norvegensis, Candida valida and Candida dubliniensis appear to be of importance in public health. 4,31 Similarly, other agents that have previously been considered environmental pollutants or of industrial importance, such as Candida utilis and Candida lipolytica, are currently identified as agents of fungemia, onychomycosis and systemic disease. 7 For this reason, it is important to study the different yeast strains obtained from pigeon samples (crop, cloaca, droppings).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pigeons and their droppings as reservoirs of Candida and other zoonotic yeasts

Medina

Fuentes

Arteaga

et al. 2017

Revista Iberoamericana de Micología

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Pigeons and their droppings as reservoirs of Candida and other zoonotic yeasts

Medina

Fuentes

Arteaga

et al. 2017

Revista Iberoamericana de Micología

View full text Add to dashboard Cite

show abstract

“…C. haemulonii , a non-albicans Candida species, does not frequently cause human infections (3). Microbiologically, the susceptibility profile of C. haemulonii shows that it is resistant to amphotericin B and other antifungal agents such as azoles (4), which have often been associated with clinical treatment failure (5, 6). No treatment regimen for invasive C. haemulonii infections has been clearly established.…”

Section: Introductionmentioning

confidence: 99%

Catheter-related Candidemia Caused by Candida haemulonii in a Patient in Long-term Hospital Care

Kim

Moon

et al. 2011

J Korean Med Sci

View full text Add to dashboard Cite

Candida haemulonii, one of the non-albicans Candida species, is an emerging yeast pathogen that is known to be resistant to amphotericin B and other antifungal agents such as azoles. These anti-fungal agents have often been associated with clinical treatment failure, so no treatment regimen has been clearly established for invasive C. haemulonii infections. We investigated a catheter-related infection of C. haemulonii candidemia in an adult patient in long-term hospital care. In the early stages, the candidemia remained persistent despite treatment with fluconazole. However, after changing the antifungal agent to caspofungin, the candidemia was resolved. Fluconazole and amphotericin B are not reliable empirical antifungal agents for invasive C. haemulonii infections, as shown in previous case reports. An echinocandin such as caspofungin may be an appropriate empirical choice of antifungal agent for an invasive C. haemulonii infection.

show abstract

“…Desde el punto de vista clínico la resistencia inicial o el desarrollo rápido de resistencia a anfotericina B constituye la característica más importante de C. lusitaniae. Muchos autores consideran que esta resistencia es adquirida aunque también se ha documentado cepas con resistencia intrínseca (1,4,7,8,15,17,24,34).…”

Section: Introduccionunclassified

Candida lusitaniae EN UN PACIENTE PEDIATRICO INMUNOCOMPROMETIDO: EXITO TERAPEUTICO DEL VORICONAZOL

Runco

Salim

2005

Bol. Micol.

View full text Add to dashboard Cite

Palabras clave: Candida lusitaniae, paciente pediátrico, Voriconazol RESUMENCandida lusitaniae es reconocida como un patógeno emergente, ocasionalmente responsable de graves infecciones nosocomiales en pacientes con compromiso inmune. Esta levadura plantea dos desafíos importantes; la posibilidad de una identificación errónea de la especie y su resistencia primaria o adquirida a la Anfotericina B. El presente trabajo informa el aislamiento en cultivos puros de C.lusitaniae desde el líquido cefalorraquídeo de un paciente pediátrico inmunocomprometido, de 5 meses de edad, hospitalizado por hidrocefalia posthemorrágia neonatal valvulada. El paciente fue tratado inicialmente con Anfotericina B, substituida posteriormente por Voriconazol. Se destaca el éxito terapéutico de éste último en la dosis usada en este caso. Luego de un prolongado período de hospitalización el paciente fue dado de alta. Consideramos que para entender la importancia clínica de esta levadura, es necesario investigaciones más completas tanto de su epidemiología como de los mecanismos de resistencia a los antifúngicos y de su frecuencia, tanto in vivo como in vitro, condiciones útiles para entender algunas de las razones de la emergencia de C. lusitaniae en clínica. ABSTRACTCandida lusitaniae is known to be an emerging pathogenous which is occasionally responsible for serious nosocomial infections in immunocompromised patients. This yeast involves two significant challenges: the possibility of a wrong identification of the species and its primary or acquired resistance to Anfotericina B. The present paper reports the isolation of C.lusitaniae in pure cultures taken from a 5-month aged immunocompromised pediatric patient who had been diagnosed with a neonatal post hemorrhagic valvular hydrocephalus. The patient was firstly treated with Anfotericena B and later on with Voriconazole. The therapeutic success of the latter medication as used in this case is pointed out. After being a long time in the hospital, the patient was sent home. In order to understand the clinical significance of this yeast, we think it is necessary to carry out further research work both in its epidemiology and in its antifungal drug resistance mechanisms together with its frequency in situ and in vitro,being the above requirements useful to recognize the reasons for. C lusitaniae emergence in the clinic.

show abstract

Sensibilidad a antifúngicos de levaduras patógenas emergentes

Cited by 29 publications

References 88 publications

Pigeons and their droppings as reservoirs of Candida and other zoonotic yeasts

Pigeons and their droppings as reservoirs of Candida and other zoonotic yeasts

Catheter-related Candidemia Caused by Candida haemulonii in a Patient in Long-term Hospital Care

Candida lusitaniae EN UN PACIENTE PEDIATRICO INMUNOCOMPROMETIDO: EXITO TERAPEUTICO DEL VORICONAZOL

Contact Info

Product

Resources

About